Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07176416 · ClinicalTrials.gov registry record
Effective Phaco Time and Endothelial Cell Loss When Using Veritas
A clinical trial of Cataract, sponsored by Aloha Vision Consultants.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT07176416: Recruiting study of Cataract, sponsored by Aloha Vision Consultants.
NCT07176416 is a study of Cataract that is actively recruiting participants, run by Aloha Vision Consultants. The registered enrollment target is 50 participants, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07176416, a study of Cataract, is actively recruiting participants, sponsored by Aloha Vision Consultants.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a single center, prospective study of cumulative dissipated energy and endothelial cells loss per phacoemulsification procedure after successful cataract surgery. Subjects will be assessed 3 months postoperatively at a single visit. Clinical evaluations will include central corneal thickness, specular microscopy, as well as measurement of visual acuities at distance.
Conditions Studied
Interventions
- DEVICE Veritas Vision System
Study Locations (1)
Hawaii
- Aloha Vision Consultants - ‘Aiea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-10-03 |
| Est. Completion | 2026-10-01 |
What NCT07176416 shows while recruiting
NCT07176416 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 1 intervention - of which Veritas Vision System is the first listed.
NCT07176416 reports a single indexed study location in Hawaii.
Frequently Asked Questions
What is clinical trial NCT07176416 about?
NCT07176416 is a clinical study titled "Effective Phaco Time and Endothelial Cell Loss When Using Veritas". This study is a single center, prospective study of cumulative dissipated energy and endothelial cells loss per phacoemulsification procedure after successful cataract surgery. Subjects will be assessed 3 months postoperatively at a single visit. Clinical evaluations will include central corneal thi...
What is the current status of trial NCT07176416?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-10-03. Estimated completion is 2026-10-01.
What conditions does trial NCT07176416 study?
This clinical trial studies the following conditions: Cataract.
What interventions are being tested in trial NCT07176416?
The interventions under investigation include: Veritas Vision System (DEVICE).
Who is sponsoring clinical trial NCT07176416?
This trial is sponsored by Aloha Vision Consultants, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07176416 being conducted?
This trial has 1 study location across Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07176416's enrollment target sits among peer trials
50 57th of 83 higher than 25 of 83 other Cataract trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cataract trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
RECRUITING
-
Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety and Workflow Study
RECRUITING · NA
-
Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC
RECRUITING · Phase 1
-
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
RECRUITING · Phase 3
-
Unity VCS: A Comparison Study Evaluating Corneal Clarity and Thickness
RECRUITING · NA
-
Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI